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Abstract 1262 
Introduction: Surgical bleeding is among the most frequent symptoms in Factor VII (FVII) deficient patients: 
in an analysis by our group, post-surgical bleeding was reported in 24% of cases (Mariani G. et al. Thromb 
Haemost 2005;93:481). A recent retrospective study showed a similar prevalence of surgical bleeding (15%) 
with a significant relation between this type of bleeding, deep hematomas and a FVII coagulant activity 
(FVIIc) of less than 7% (Benlakal F et al. J Thromb Haemost 2011;9:1149). Little is known about prevention 
of bleeding in ‘minor surgical interventions’, important tools inmodern medicine, bearing not a negligible 
risk of bleeding, as local hemostasis may not always be punctually achieved. 
Aim: Analysis of Replacement Therapy (RT) for minor surgeries in patients with FVII deficiency, 
prospectively reported in the Seven treatment Evaluation Registry (STER). Clinicaltrials.gov identifier: 
NCT01269138. 
Methods: Analysis of RTs used in 38 minor surgical procedures (34 patients; FVIIc:<1–20%). Minor 
surgical procedures were defined as suggested byKitchens (Surgery and hemostasis. Textbook of 
Consultative Hemostasis and Thrombosis. 2007). 
Results: Reported interventions included: oral surgery (n=15), endoscopic biopsies (n=7), catheter insertions 
(n=3), ear-nose-throat and head-neck (n=5),mixed type (n=8). RT schedules were based on recombinant-
activated FVII (rFVIIa; n=29), plasma-derived FVII (pdFVII; n=8), or Fresh-Frozen-Plasma (n=1). One-day 
RT schedule was employed in 27 procedures, 2–10 days in 11 procedures. Total doses ranged from 7.2–510 
μg/kg (rFVIIa) and 9–300 IU/kg (pdFVII). FFP was given at a total dose of 50 ml/kg (1-day treatment, split 
into 4 doses of 12.5 ml). Antifibrinolytics were administered together with RT in 16 procedures (11 dental) 
for a minimum of 1 day to a maximum of 7 days. No bleeding nor thrombotic events occurred; one patient 
developed an inhibitor  
 
 
  
Conclusion: For most of the uncomplicated minor surgery procedures (single dental extractions, catheter 
insertions, endoscopic biopsies), one-day RT is sufficient with low to medium doses of rFVIIa (median 25 
μg/Kg/bw) or pdFVII (median 18.5 UI/Kg/bw), possibly with more than one administration. In complicated 
and more elaborate interventions, longer-lasting RT schedules and higher doses may be needed. 
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